Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLK-1 UsiRNA-DiLA2
- Development stage
- Preclinical
- Lead developer
- Marina Biotech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intravesical, Intravenous
01
Overview
PLK-1 UsiRNA-DiLA2 is a preclinical-stage RNA interference (RNAi) therapeutic developed by Marina Biotech (formerly MDRNA, Inc.). The drug consists of a UsiRNA (unlocked nucleic acid-modified siRNA) designed to target and silence the mRNA of polo-like kinase 1 (PLK1), a critical regulator of the cell cycle (specifically the G2/M transition and cytokinesis). The UsiRNA is delivered using Marina Biotech's proprietary DiLA2 (Di-alkylated Amino Acid) lipid-based liposomal delivery system. In preclinical studies, the therapeutic demonstrated significant knockdown of PLK1 expression and tumor growth inhibition in models of bladder cancer, hepatocellular carcinoma, and malignant ascites associated with ovarian and gastrointestinal cancers.
- Other names
- PLK1 UsiRNA-DiLA2PLK-1 UsiRNA-DiLA2PLK 1 UsiRNA-DiLA2PLK1 UsiRNA/DiLA2
02
Targets
PLK1 (Polo like kinase 1)
Beyond the preview
Go deeper on PLK-1 UsiRNA-DiLA2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLK-1 UsiRNA-DiLA2.